<DOC>
	<DOCNO>NCT00088868</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) , work different way stop cancer cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose 17-DMAG treating patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>17-Dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) Treating Patients With Advanced Solid Tumor Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) patient advance malignant solid tumor lymphoma . - Determine dose-limiting toxic effect toxicity profile drug patient . Secondary - Compare effect drug heat shock protein 90 ( Hsp90 ) client proteins assayed peripheral blood mononuclear cell ( PBMC ) v tumor tissue patient treat drug . - Correlate disturbance key signal pathways administration drug patient . - Determine dose alters key protein majority patient treat drug . - Correlate serum proteomic pattern target interaction DMAG clinical effect patient treated drug . - Determine pharmacokinetics drug patient . OUTLINE : This single-center , dose-escalation study . Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) IV 1-2 hour day 1 4 day 2 5 weekly 4 week . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos 17-DMAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat MTD . PROJECTED ACCRUAL : Approximately 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor OR lymphoma Metastatic unresectable disease Standard curative palliative measure available OR associate minimal survival benefit No known brain metastasis Treated brain metastasis allow provide stable ≥ 6 month without steroid antiseizure medication PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hemoglobin &gt; 8 g/dL Hepatic AST ALT ≤ 2 time upper limit normal Bilirubin ≤ 1.5 time normal PT PTT ≤ 1.5 time normal ( unless due presence lupus anticoagulant stable anticoagulation ) Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No orthostatic hypotension &gt; grade 2 ( require brief fluid replacement therapy OR physiological consequence ) No New York Heart Association class III IV heart failure LVEF ≥ 40 % MUGA QTc ≤ 450 msec ( 470 msec woman ) No congenital long QT syndrome No myocardial infarction within past year No active ischemic heart disease within past year No history uncontrolled dysrhythmias No history serious ventricular arrhythmia ( ventricular fibrillation ventricular tachycardia &gt; 3 premature ventricular contraction row ) Not require antiarrhythmic drug No poorly control angina No left bundle branch block Pulmonary No uncontrolled symptomatic pulmonary disease , include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Severe chronic obstructive/restrictive pulmonary disease require daily chronic medication oxygen Must meet Medicare criteria home oxygen No sufficiently compromise pulmonary status measure baseline pulmonary function test DLCO Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No known HIV positivity No hyponatremia indicate sodium &lt; 130 mmol/L No known immunodeficiency syndromes No history allergic reaction attribute compound similar chemical biological composition 17dimethylaminoethylamino17demethoxygeldanamycin ( geldanamycin 17AAG ) No concurrent uncontrolled illness No active ongoing uncontrolled infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy recover No concurrent prophylactic growth factor Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin , 8 week UCN01 ) recover Endocrine therapy See Disease Characteristics Concurrent hormonal therapy prostate cancer allow provide patient metastatic disease progress despite prior hormonal therapy Radiotherapy More 4 week since prior radiotherapy recover No prior radiotherapy include heart field ( e.g. , mantle radiotherapy ) Surgery At least 4 week since prior major surgery Other At least 2 week since prior participation phase 0 study Concurrent bisphosphonates cancer allow Concurrent preventative dos aspirin nonsteroidal antiinflammatory drug allow No concurrent drug may prolong QTc interval No concurrent full anticoagulation regular basis No concurrent prophylactic antiemetic No concurrent investigational agent therapies No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>